Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Decoy Therapeutics (Nasdaq: DCOY) announced it regained compliance with Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement) effective March 31, 2026. The company is reported to be in compliance with all other continued listing requirements, but will be subject to a Mandatory Panel Monitor for one year from that date.
If the Listing Qualifications Staff finds renewed noncompliance during the one-year monitoring period, Nasdaq may issue a delisting determination letter and the company could request a hearing with the Nasdaq Hearings Panel.
Positive
- Regained Nasdaq minimum bid price compliance on March 31, 2026
- Now in compliance with all other applicable Nasdaq continued listing requirements
Negative
- Subject to a Mandatory Panel Monitor for one year from March 31, 2026
- Possible delisting if Listing Qualifications Staff finds noncompliance during the monitoring period
News Market Reaction – DCOY
In the Apr 2 session, DCOY declined 8.23%, reflecting a notable negative market reaction. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 11 | AI partnership launch | Positive | -4.8% | Announced AI-driven peptide design and simulation platform with Quantori and Google Cloud. |
| Mar 05 | Reverse stock split | Neutral | -11.3% | Approved 1-for-12 reverse split aimed at regaining Nasdaq minimum bid compliance. |
| Feb 11 | Investor platform join | Positive | -3.0% | Joined Webull Corporate Connect to broaden communication with investors and shareholders. |
| Feb 05 | Investor webinar | Positive | -1.6% | Planned presentation in Webull webinar highlighting antiviral peptide conjugate therapeutics. |
| Feb 04 | Access agreement update | Positive | -7.6% | Discussed Global Access Commitment Agreement with Gates Foundation and IMP3ACT platform plans. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational and strategic news has repeatedly been followed by negative 24-hour price reactions.
Over the past few months, Decoy announced a 1-for-12 reverse stock split on Mar 5, 2026, an AI-driven peptide design partnership with Quantori on Mar 11, 2026, and several investor-engagement initiatives, including Webull Corporate Connect participation and a Gates Foundation-related access segment in early February. Each event was followed by a negative 24-hour price reaction, suggesting a pattern where constructive corporate developments have not translated into short-term price strength ahead of today’s compliance news.
Key Terms
listing rule 5550(a)(2) regulatory
minimum bid price requirement regulatory
mandatory panel monitor regulatory
nasdaq hearings panel regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Nasdaq further notified the Company that it will be subject to a Mandatory Panel Monitor for a period of one year from March 31, 2026. If, within that one-year monitoring period, the Listing Qualifications Staff finds the Company out of compliance with the Minimum Bid Price Requirement that was the subject of the exception, the Staff will issue a delisting determination letter and the Company will have the opportunity to request a hearing with the Nasdaq Hearings Panel.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "can," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected.
View original content to download multimedia:https://www.prnewswire.com/news-releases/decoy-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302732823.html
SOURCE Decoy Therapeutics, Inc